The nasal cannula is a device that is used for supplying oxygen or increasing the airflow of oxygen to a patient suffering from respiratory diseases. This device is made up of lightweight plastic or silicon tubes which split into two prongs which are placed in the nostrils of the patient for oxygen supply. The other end of this tube is connected to an oxygen generator or flow meter. This nasal tube carries about 1–3 liters of oxygen per minute. It can be different as per requirement of the patients. The increasing prevalence of respiratory diseases is expected to drive the nasal cannula market. According to a study published on September 29, 2020, by the National Center for Biotechnology Information (NCBI), 39% of COVID-19 patients suffered from acute respiratory distress syndrome, indicating a high need for providing oxygen needs for patients, which is expected to grow the nasal cannula market. The following flowchart is obtained from the World Health Organization - United Nations Children's Fund (WHO-UNICEF) about technical specifications and guidelines for oxygen therapy devices which is indicating the work flow used of oxygen system provided to patients. Thus, the nasal cannula is used for the delivery of oxygen.
Global Nasal Cannula Market - Impact of the Coronavirus (COVID-19) Pandemic
COVID-19 has affected the respiratory systems of patients, causing a low level of oxygen in patients, needed to provide supplemental oxygen to recover from respiratory issues, which is expected to drive the growth of the global nasal cannula market over the forecast period. For instance, an article published on October 1, 2020, in PubMed about High-Flow Nasal Cannula (HFNC) therapy for COVID-19, states that the use of a high-flow nasal cannula for critically ill patients with COVID-19 helps in restoring oxygenation for severe acute respiratory failure issues. This study suggested that High Flow Nasal Cannulas (HFNC) reduced intubation rate and mortality rate in critically ill patients due to COVID-19 and study concluded that HFNC is safe for providing standard oxygen to COVID-19 patients suffering from respiratory failure.
Increasing awareness about respiratory diseases by the market players is expected to increase the growth of the nasal cannula market over the forecast period. For instance, in June 2021, the Ministry of health and family welfare, India issued guidelines for operationalization of COVID-19 care services for children and adolescents, which state that precautions and guidelines should be followed for children affected by COVID-19. Children must undergo RTPCR and CBNAAT tests for the diagnosis of COVID-19. After the confirm report, children with mild symptoms can be treated at home, but for critical conditions such as difficulty in respiration and uncertain oxygen saturation, they must be admitted to COVID centers having facilities for oxygen therapy , ICU and high dependency unit (HDU).
The global nasal cannula market is estimated to be valued at US$ 6,801.7 Mn in 2021 and is expected to exhibit a CAGR of 6.4 % over the forecast period (2021-2028).
Figure 1: Global Nasal Cannula Market Share, (%), Analysis, By Application, 2021
Increasing research and development activities by the market players for developing the treatment for respiratory diseases is expected to drive the growth of the global nasal cannula market over the forecast period.
Market players are involved in research and development activities to develop treatments for respiratory diseases. This is expected to increase the growth of the nasal cannula market over the forecast period. For instance, In Karger which is database where scientific and medical related articles and latest researches in life sciences are published, In February 2020 study published about clinical evidence of nasal high flow therapy (NHFT) for COPD (Chronic Obstructive Pulmonary Disease) patients stated that studies were conducted on patients with different medical conditions, such as long-term NHFT in stable patients with COPD, chronic bronchiectasis, chronic hypoxemic failure, and chronic hypercapnic respiratory failure , where this study resulted as the adherence of nasal high flow therapy needed for COPD or bronchiectasis was 1.6 hrs. per day ,for chronic hypoxemic failure it was 6 hrs per day and for chronic hypercapnic 20L / min were supply for 6 weeks.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 6,801.7 Mn |
| Historical Data for: | 2018 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 6.4% | 2028 Value Projection: | US$ 10,491.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic plc., Maquet Holding B.V. & Co. KG, Edward LifeSciences Corp., Terumo Corporation, Sorin Group, Medin Medical innovations, Flexicare Medical, Smiths Medical, Teleflex Incorporated, Vapotherm Inc., Salter Labs, Well Lead Medical Co. Ltd., Drive Devilbiss International, Allied Healthcare Products, Besmed Health Business Corp., and Fairmont Medical. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Market players are indulged in providing treatments for the respiratory diseases by providing supplemental oxygen. This is expected to increase the growth of the global nasal cannula market over the forecast period.
Market players are engaged in providing required devices and treatments for respiratory issues caused due to various factors such as COVID-19, asthma, and lung cancer, which is expected to drive the growth of the nasal cannula market over the forecast period. For instance, on July 17, 2020, the health minister of Tamil Nadu sanctioned US$ 10.2 million to buy 2,414 high-flow nasal cannulas to manage patients with breathlessness due to COVID-19.These high flow nasal cannulas were used to reduce distress in patients and help with quick recovery from affected lungs.
Global Nasal Cannula Market – Restraints
The increasing prevalence of respiratory diseases globally indicates the need for advanced technologies for healthcare services to provide oxygen supply to patients, so there are many alternative options available in market, which is expected to hamper the growth of the nasal cannula market over the forecast period. For instance, the availability of options such as full face mask, full mask with tubing and venturi mask which can be used for supplying oxygen to the patient can hamper the market of nasal cannulas.
The increasing use of nasal cannula can also cause side effects such as the transmission of pathogenic viruses through nasal cannula that can cause infection in patients, which is expected to hamper the growth of the market over the forecast period. For instance, an article by the Swedish agency for health technology assessment and assessment of social services (SBU) on August 6, 2020, stated the risk of viral infection transmission to patients via high-flow nasal cannula while providing oxygen therapy to patients. A patient can be infected through aerosol transmission, which means inhalation of viruses through the nostrils.
Global Nasal Cannula Market – Regional Analysis
On the basis of region, the global nasal cannula market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in global nasal cannula market, owing to the developments of nasal cannula treatments, which is expected to drive the growth over the forecast period. For instance, on July 28, 2021, Vyaire Medical, a U.S based company launched low flow oxygen therapy device called Airlife Open Oxygen Mask. Vyaire Medical is a one of the leading manufacturers of medical devices. The device, Airlife open oxygen mask, is constructed from patented designs. This device has ability to provide 1L- 15L per minute oxygen without disturbing patient.
Furthermore, Europe is also estimated to witness significant growth in the global nasal cannula market, owing to the increasing prevalence of premature birth, which is expected to drive the nasal cannula market over the forecast period. For instance, Medin Medical Innovations GmbH, Germany based company which is a leading manufacturer of nasal cannula for premature infants has developed Nuflow. This Nuflow nasal cannula is made up of soft and compatible silicone which provides oxygen at 8Lit / min to infants suffering from heart and lung problems.
Figure 2: Global Nasal Cannula Market (US$ Mn), by Region, 2021
Global Nasal Cannula Market – Competitive Landscape
Major players operating in the global nasal cannula market include Medtronic plc., Maquet Holding B.V. & Co. KG , Edward LifeSciences Corp., Terumo Corporation, Sorin Group, Medin Medical innovations, Flexicare Medical, Smiths Medical, Teleflex Incorporated, Vapotherm Inc., Salter Labs, Well Lead Medical Co. Ltd., Drive Devilbiss International, Allied Healthcare Products, Besmed Health Business Corp., and Fairmont Medical.
The nasal cannula device is used to deliver oxygen to patients with respiratory diseases such as asthma, lung cancer, pneumonia, Chronic Obstructive Pulmonary Diseases (COPD), and pulmonary fibrosis. This device is made up of plastic or silicon material and has a tube-like structure with two prongs to connect nostrils for providing oxygen. These tubes are placed behind the ear to allow for better adjustment of the prongs. These nasal cannula tubes are available at a low cost, which drives the growth of the nasal cannula market. There are different types of nasal cannulas available in the market which are used for pre-mature infants, adults suffering from respiratory diseases, patients with lung cancer, or patients with respiratory failure due to COVID-19.
Market Dynamics
Market players are indulged in inorganic activities such as collaborations in order to increase research and development activities for the treatment of respiratory diseases. This is expected to increase the growth of the global nasal cannula market over the forecast period. For instance, on February 17, 2021, Vir Biotechnology and GSK expanded their coronavirus collaboration to develop advanced therapeutics for influenza and respiratory viruses. Vir Biotechnology is immunology focused company aims for developing technologies for infectious diseases and GSK is manufacturer of vaccines, innovative medicines and healthcare products. The aim of this collaboration is to use Vir’s monoclonal antibody technology to create an identical new anti-viral antibodies for therapeutic treatments and preventions for COVID -19 or future outbreaks of the pathogenic diseases.
Increasing awareness for the treatment as well as management of respiratory diseases is expected to increase the growth of the global nasal cannula market over the forecast period. For instance, a news published on September 9, 2021 by AstraZeneca is a global pharmaceutical business company and manufacturer of innovative medicines has launched program called as International Respiratory Coalition for Urgent need for national respiratory strategies after COVID-19 to drive the improvements in healthcare systems resilience. It is coordinated with European Respiratory Society .This program will provide funding or contribution with expertise for delivering facilities to patients suffering for respiratory diseases.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients